Clinical data | |
---|---|
Other names | (2S)-1-pyrrolidine-2-carboxamide |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H27Cl2N3O7S |
Molar mass | 620.50 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Relcovaptan (SR-49059) is a non-peptide vasopressin receptor antagonist, selective for the V1a subtype. It has shown positive initial results for the treatment of Raynaud's disease and dysmenorrhoea, and as a tocolytic, although it is not yet approved for clinical use.
References
- Lemmens-Gruber R, Kamyar M (August 2006). "Vasopressin antagonists". Cellular and Molecular Life Sciences. 63 (15): 1766–79. doi:10.1007/s00018-006-6054-2. PMC 11136164. PMID 16794787. S2CID 30709102.
- Decaux G, Soupart A, Vassart G (May 2008). "Non-peptide arginine-vasopressin antagonists: the vaptans". Lancet. 371 (9624): 1624–32. doi:10.1016/S0140-6736(08)60695-9. PMID 18468546. S2CID 1245079.
This hormonal preparation article is a stub. You can help Misplaced Pages by expanding it. |